诺诚健华医药有限公司（09969）于2026年1月6日公告了截至2025年12月31日的证券变动月报。该报告显示，公司在12月期间并未发生新增股份发行、购回或注销，整体股本维持不变。
\n\n根据公告，公司法定注册股本维持在USD 50,000（对应25,000,000,000股，面值USD 0.000002）。于香港联交所上市的普通股数量依旧为1,493,798,235股，另有2,486,000股库存股份，总数为1,496,284,235股。截至月末，上海证券交易所科创板上市的普通股则保持在268,359,717股。
\n\n报告亦披露，2023年人民幣股股份激励计划与2024年人民幣股股份激励计划均有部分限制性股份失效，但本月内未新增发行或从库存股份转让。公司已发行股份总数未发生任何变动，股本结构整体保持稳定。
\n\n公告由公司主席兼执行董事崔霽松博士签署。公司重申遵守香港联交所《上市规则》和相关法律规定，报告期内无任何其他股本变动或购回活动。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.